The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A

N8-GP (turoctocog alfa pegol) is a recombinant, glycoPEGylated, extended half-life, factor VIII replacement product. Here, we examined the immunogenicity, safety, and efficacy of N8-GP in previously untreated patients (PUPs). pathfinder6 is an ongoing, open-label, phase 3 trial that enrolled PUPs wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Male, Christoph, Königs, Christoph, Dey, Sohan, Matsushita, Tadashi, Millner, Anders Holm, Zak, Marek, Young, Guy, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979760/
https://www.ncbi.nlm.nih.gov/pubmed/35858373
http://dx.doi.org/10.1182/bloodadvances.2022007529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979760/
https://www.ncbi.nlm.nih.gov/pubmed/35858373
http://dx.doi.org/10.1182/bloodadvances.2022007529

Ejemplares similares